サポート ブログ Antibody History and Development

Antibody History and Development

Biointron 2024-01-20 Read time: 2 mins
history.jpg
Image credit: DOI: 10.1186/s12929-019-0592-z

The history of antibody research and development dates back to the late 19th century, when the German scientist Emil von Behring discovered that serum from an animal previously infected with diphtheria could be used to prevent the disease. 

Since then, the study of antibodies has led to significant advancements in our understanding of the immune system and the development of treatments for a wide range of diseases. In the early 1970s, the hybridoma technology was developed, which allowed for the production of monoclonal antibodies (mAbs) – antibodies that are identical and specific to a single antigen. This technology revolutionized the field of antibody research and led to the development of many life-saving drugs. 

More recently, the field of recombinant antibody technology has emerged, which allows for the production of fully human antibodies in large quantities. These antibodies are generated by combining a human antibody gene with a host cell, such as Chinese hamster ovary (CHO) cells, to create a recombinant cell line. Recombinant antibody technology has become a powerful tool in drug discovery and development, allowing for the rapid production of high-quality, fully human antibodies for use in therapeutic applications. 

At Biointron, we specialize in the production of high-quality recombinant antibodies for use in drug discovery and development. Our state-of-the-art platform enables the rapid expression of a large number of antibodies in CHO cells, with amounts guaranteed from 100ug to 100g. With our technology, we can deliver fully human antibodies in just two weeks from gene synthesis to purified antibody. Contact us to learn more about our recombinant antibody services and how we can support your drug discovery efforts. 

Subscribe to our ブログ

Recent ブログ

The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.

Jul 12, 2024
ブログ

Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.

Jul 10, 2024
ブログ

Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.

Jul 08, 2024
ブログ

Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.

Jul 04, 2024
ブログ

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。